Literature DB >> 9592049

Pharmacological characterization and differentiation of non-cholinergic nucleus basalis neurons in vitro.

P Fort1, A Khateb, M Serafin, M Mühlethaler, B E Jones.   

Abstract

Using intracellular recordings in guinea pig brain slices, the pharmacology of electrophysiologically identified and immunohistochemically confirmed non-cholinergic nucleus basalis neurons was studied to determine their response to the major neurotransmitters of the subcortical afferents to this region. The cells were differentiated into three types: Type A cells (approximately 44%) were depolarized by noradrenaline (NA) and muscarine, Type B cells (approximately 23%) were depolarized by NA but hyperpolarized by muscarine, and Type C cells (approximately 15%) were hyperpolarized by both agonists. These cell types were also differentially responsive to serotonin (hyperpolarizing B, C) and histamine (depolarizing A, B). Accordingly, the non-cholinergic neurons share certain discharge properties but appear nonetheless to comprise distinct types which respond differentially to the major modulatory neurotransmitters and thus play potentially different roles in cortical modulation across the sleep-wake cycle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592049     DOI: 10.1097/00001756-199801050-00013

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  11 in total

1.  Discharge profiles of juxtacellularly labeled and immunohistochemically identified GABAergic basal forebrain neurons recorded in association with the electroencephalogram in anesthetized rats.

Authors:  I D Manns; A Alonso; B E Jones
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

2.  Discharge properties of juxtacellularly labeled and immunohistochemically identified cholinergic basal forebrain neurons recorded in association with the electroencephalogram in anesthetized rats.

Authors:  I D Manns; A Alonso; B E Jones
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

3.  Activity of neurons in the basal magnocellular nucleus during performance of an operant task.

Authors:  B V Chernyshev; Ya A Panasyuk; I I Semikopnaya; N O Timofeeva
Journal:  Neurosci Behav Physiol       Date:  2004-11

4.  The preoptic hypothalamus and basal forebrain play opposing roles in the descending modulation of sleep and wakefulness in infant rats.

Authors:  Ethan J Mohns; Karl A E Karlsson; Mark S Blumberg
Journal:  Eur J Neurosci       Date:  2006-03       Impact factor: 3.386

Review 5.  Neurobiology of waking and sleeping.

Authors:  Barbara E Jones
Journal:  Handb Clin Neurol       Date:  2011

6.  Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins.

Authors:  Pablo Henny; Barbara E Jones
Journal:  J Comp Neurol       Date:  2006-12-01       Impact factor: 3.215

7.  Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons.

Authors:  E G Cape; B E Jones
Journal:  J Neurosci       Date:  1998-04-01       Impact factor: 6.167

8.  Intrinsic voltage dynamics govern the diversity of spontaneous firing profiles in basal forebrain noncholinergic neurons.

Authors:  Saak V Ovsepian; J Oliver Dolly; Laszlo Zaborszky
Journal:  J Neurophysiol       Date:  2012-04-11       Impact factor: 2.714

Review 9.  Principal cell types of sleep-wake regulatory circuits.

Authors:  Barbara E Jones
Journal:  Curr Opin Neurobiol       Date:  2017-04-19       Impact factor: 6.627

10.  The α1 adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar-Kyoto rats.

Authors:  Benjamin M Laitman; Nicholas D Gajewski; Graziella L Mann; Leszek Kubin; Adrian R Morrison; Richard J Ross
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-15       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.